Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Equity Average: 2021-2025

Historic Equity Average for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $515.2 million.

  • Kiniksa Pharmaceuticals International's Equity Average rose 18.15% to $515.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $515.2 million, marking a year-over-year increase of 18.15%. This contributed to the annual value of $438.6 million for FY2024, which is 5.06% up from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's Equity Average is $515.2 million, which was up 8.18% from $476.2 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Equity Average ranged from a high of $515.2 million in Q3 2025 and a low of $159.9 million during Q2 2022.
  • Moreover, its 3-year median value for Equity Average was $435.4 million (2024), whereas its average is $436.9 million.
  • Its Equity Average has fluctuated over the past 5 years, first slumped by 36.87% in 2022, then surged by 150.75% in 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Equity Average (Quarterly) stood at $199.5 million in 2021, then skyrocketed by 95.49% to $390.1 million in 2022, then grew by 8.18% to $422.0 million in 2023, then increased by 3.73% to $437.7 million in 2024, then increased by 18.15% to $515.2 million in 2025.
  • Its Equity Average stands at $515.2 million for Q3 2025, versus $476.2 million for Q2 2025 and $448.0 million for Q1 2025.